NeuroOne(R) Advances Brain Drug Delivery Platform Through Collaboration With University of MinnesotaSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) Medical Technologies Announces Reverse Stock Split to Regain Nasdaq ComplianceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) Medical Technologies Announces Reverse Stock Split to Regain Nasdaq ComplianceEDEN PRAIRIE, MINN. - April 14, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it will effect a 1-for-6 reverse stock split of its common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on April 15, 2026, with the company’s common stock expected to begin trading on a split-adjusted basis at the opening of the market on Thursday, April 16, 2026.
NeuroOne(R) Issues Shareholder Letter and Provides Corporate UpdateCommercial Momentum Accelerates with Record OneRF® Procedure Volume in Fiscal Q1 ‘26 and Early Trigeminal Success
NeuroOne(R) Appoints Jason Mills to the Board of DirectorsVeteran Med-Tech Research Analyst & Public Company Executive to Bring Strategic Experience, Industry Relationships and Vision to the Board
NeuroOne(R) Medical Technologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) Medical Technologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)EDEN PRAIRIE, MINN. - April 2, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that, effective April 1, 2026, its independent directors approved an equity award under NeuroOne’s 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
NeuroOne(R) Successfully Completes Limited Market Release of OneRF(R) Trigeminal Nerve Ablation SystemSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) Successfully Completes Limited Market Release of OneRF(R) Trigeminal Nerve Ablation System12 Patients Successfully Treated Across Three Leading Centers, With All Patients Reporting Freedom From Pain*
NeuroOne(R) Announces Publication of Clinical Experience With Its OneRF(R) sEEG-Guided Radiofrequency Ablation TechnologySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) Announces Publication of Clinical Experience With Its OneRF(R) sEEG-Guided Radiofrequency Ablation TechnologyPeer-Reviewed Case Series Supports Safe Integration into Existing Stereotactic Workflow, Bedside Treatment Capability, and Reductions in Seizure Burden in Patients with Drug-Resistant Epilepsy*
NeuroOne(R) to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference March 17, 2026 at 1:20 p.m. Eastern TimeSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference March 17, 2026 at 1:20 p.m. Eastern TimeEDEN PRAIRIE, MINN. - March 11, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that the Company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference virtually on March 17, 2026.
NeuroOne(R) Issues Shareholder Letter and Provides Corporate UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) Appoints David Wambeke as Chief Business Officer; Concurrently Completes Insider Purchase of 1 Million SharesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) Appoints David Wambeke as Chief Business Officer; Concurrently Completes Insider Purchase of 1 Million SharesProven Healthcare Leader with Capital Markets Expertise to Support Strategic Expansion; Personal Investment Signals Strong Conviction in Company’s Strategic Growth
NeuroOne(R) to Host Virtual Investor Webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern TimeSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) to Host Virtual Investor Webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern TimeEDEN PRAIRIE, MINN - February 26, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, announced today that it will hold a virtual investor webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time.
NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026Nearly 50% of all Ablations Since OneRF® Ablation System Product Launch in 2024 were Performed in Fiscal Q1 2026, Showing Growing Adoption
NeuroOne(R) to Report First Quarter Fiscal Year 2026 Financial Results on Tuesday, February 17 at 8:30 a.m. Eastern TimeSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NeuroOne(R) to Report First Quarter Fiscal Year 2026 Financial Results on Tuesday, February 17 at 8:30 a.m. Eastern TimeEDEN PRAIRIE, MINN. - February 4, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, will release financial results for its fiscal first quarter ended December 31, 2025, before market open on February 17, 2026.
NeuroOne(R) Appoints Jason Mills to the Board of DirectorsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
